Ironwood Pharmaceuticals Inc

Insider buying fuels optimism for Ironwood Pharma: executives pile into Class A shares, signaling confidence in the pipeline and long‑term upside.

Insider buying dominates Ironwood: Ronald’s modest sell under a Rule 10b‑5 plan contrasts with Director Denner’s aggressive accumulation, signaling bullish confidence amid strong earnings and a $4.30 price well below year highs.